Blue Dog Democrat FDA reform bill likely to focus on third-party review.
This article was originally published in The Tan Sheet
Executive Summary
FDA REFORM BILL FOCUSING ON THIRD-PARTY REVIEW PLANNED BY BLUE DOG COALITION of centrist House Democrats. A bill under development by the Blue Dog Coalition is understood to be focusing on third-party reviews as a central element and likely would avoid controversial elements such as permitting off-label information dissemination and imposing "hammers" if FDA failed to meet performance goals.